Albendazole: Difference between revisions
(added info) |
(added info) |
||
| Line 5: | Line 5: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*Microsporidiosis: 400 mg po bid | |||
*neurocysticerosis: < 60 kg: 15 mg/kg/day PO BID x 8-30 days, max 800 mg/day. >60 kg: 400 mg PO BID x 8-30 days | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*neurocysticerosis: < 60 kg: 15 mg/kg/day PO BID x 8-30 days, max 800 mg/day. >60 kg: 400 mg PO BID x 8-30 days | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]:C | ||
*Lactation: | *Lactation: unknown | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: not defined | ||
**Pediatric | **Pediatric: not defined | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: not defined | ||
**Pediatric | **Pediatric: not defined | ||
==Contraindications== | ==Contraindications== | ||
| Line 23: | Line 26: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*leukopenia | |||
*neutropenia | |||
*pancytopenia | |||
*acute renal failure | |||
*hepatitis | |||
*SJS | |||
===Common=== | ===Common=== | ||
*abnormal LFT's | |||
*abdominal pain | |||
*nausea/vomiting | |||
*headache | |||
*dizziness | |||
*alopecia | |||
*fever | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 8-12 hour | ||
*Metabolism: | *Metabolism: liver | ||
*Excretion: | *Excretion: bile | ||
*Mechanism of Action: | *Mechanism of Action: inhibits tublin polymerization | ||
==See Also== | ==See Also== | ||
Revision as of 10:58, 15 May 2015
General
- Type: antiparasitic
- Dosage Forms: 200 mg
- Common Trade Names:Albenza
Adult Dosing
- Microsporidiosis: 400 mg po bid
- neurocysticerosis: < 60 kg: 15 mg/kg/day PO BID x 8-30 days, max 800 mg/day. >60 kg: 400 mg PO BID x 8-30 days
Pediatric Dosing
- neurocysticerosis: < 60 kg: 15 mg/kg/day PO BID x 8-30 days, max 800 mg/day. >60 kg: 400 mg PO BID x 8-30 days
Special Populations
- Pregnancy Rating:C
- Lactation: unknown
- Renal Dosing
- Adult: not defined
- Pediatric: not defined
- Hepatic Dosing
- Adult: not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- leukopenia
- neutropenia
- pancytopenia
- acute renal failure
- hepatitis
- SJS
Common
- abnormal LFT's
- abdominal pain
- nausea/vomiting
- headache
- dizziness
- alopecia
- fever
Pharmacology
- Half-life: 8-12 hour
- Metabolism: liver
- Excretion: bile
- Mechanism of Action: inhibits tublin polymerization